Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia
Brief Summary: This Phase 3, randomized, double-blind, placebo-controlled study is to evaluate the effect of idelalisib in combination with rituximab on the onset, magnitude, and duration of tumor control in participants previously treated for chronic lymphocytic leukemia (CLL). Eligible patients will be randomized with a 1:1 ratio into 1 of the 2 treatment arms to receive either idelalisib plus rituximab or placebo plus rituximab. Participants who are tolerating primary study therapy but experience definitive CLL progression are eligible to receive active idelalisib therapy in the extension study, GS-US-312-0117.


Options:
A: Arm Label: Idelalisib + rituximab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Idelalisib, Drug: Rituximab | Arm Label: Placebo + rituximab; Type: PLACEBO_COMPARATOR; Interventions: Drug: Rituximab, Drug: Placebo to match idelalisib | Intervention Type: DRUG; Name: Idelalisib; Assigned to Arm(s): Idelalisib + rituximab | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Idelalisib + rituximab, Placebo + rituximab | Intervention Type: DRUG; Name: Placebo to match idelalisib; Assigned to Arm(s): Placebo + rituximab
B: Arm Label: Arm A (PCO, closed to accrual as of 8/23/2011); Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide, Other: Laboratory Biomarker Analysis, Biological: Ofatumumab, Drug: Pentostatin | Arm Label: Arm B (PCO with ofatumumab consolidation); Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide, Other: Laboratory Biomarker Analysis, Biological: Ofatumumab, Drug: Pentostatin | Intervention Type: DRUG; Name: Cyclophosphamide; Assigned to Arm(s): Arm A (PCO, closed to accrual as of 8/23/2011), Arm B (PCO with ofatumumab consolidation) | Intervention Type: OTHER; Name: Laboratory Biomarker Analysis; Assigned to Arm(s): Arm A (PCO, closed to accrual as of 8/23/2011), Arm B (PCO with ofatumumab consolidation) | Intervention Type: BIOLOGICAL; Name: Ofatumumab; Assigned to Arm(s): Arm A (PCO, closed to accrual as of 8/23/2011), Arm B (PCO with ofatumumab consolidation) | Intervention Type: DRUG; Name: Pentostatin; Assigned to Arm(s): Arm A (PCO, closed to accrual as of 8/23/2011), Arm B (PCO with ofatumumab consolidation)
C: Arm Label: Bendamustine + GA101 + Ibrutinib; Type: EXPERIMENTAL; Interventions: Drug: Bendamustine, Drug: GA101, Drug: Ibrutinib | Intervention Type: DRUG; Name: Bendamustine; Assigned to Arm(s): Bendamustine + GA101 + Ibrutinib | Intervention Type: DRUG; Name: GA101; Assigned to Arm(s): Bendamustine + GA101 + Ibrutinib | Intervention Type: DRUG; Name: Ibrutinib; Assigned to Arm(s): Bendamustine + GA101 + Ibrutinib
D: Arm Label: Idelalisib & Ofatumumab; Type: EXPERIMENTAL; Interventions: Drug: Idelalisib, Drug: Ofatumumab | Intervention Type: DRUG; Name: Idelalisib; Assigned to Arm(s): Idelalisib & Ofatumumab | Intervention Type: DRUG; Name: Ofatumumab; Assigned to Arm(s): Idelalisib & Ofatumumab

Answer: A